Qurient Co., Ltd.

A115180

KR7115180002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 25/06/2024 BST			5-day change	1st Jan Change
3,690 ^KRW	-0.14%		-0.54%	-20.99%

05-21	Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC	CI
05-17	Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI

Qurient Co., Ltd. announced that it has received KRW 5.999997188 billion in funding from Premier Partners, LLC

December 26, 2023

On December 27, 2023, Qurient Co., Ltd. closed the transaction. The transaction for shares included participation from individual investor, Ki-yeon for 237,868 shares, Yoo Chang-yeon for 237,868 shares, Byeon Young-han for 118,934 shares.

Latest news about Qurient Co., Ltd.

Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC	05-21	CI
Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	05-16	CI
Qurient Co., Ltd. announced that it expects to receive KRW 13.499998256 billion in funding from DongKoo Bio & Pharma Co., Ltd. and another investor	04-11	CI
Qurient Co., Ltd. announced that it has received KRW 5.999997188 billion in funding from Premier Partners, LLC	12-26	CI
Qurient Co., Ltd. announced that it expects to receive KRW 5.99999268 billion in funding from Premier Partners, LLC	12-18	CI
Qurient Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Qurient Co. Ltd. and TB Alliance Announces Exclusive License Agreement for Telacebec	03/02/23	CI
Qurient Co., Ltd. Announces Dosing of First Patient in Q702 in Combination with KEYTRUDA® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid Tumors	31/01/23	CI
Qurient Co. Ltd Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors	01/12/22	CI
Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors	01/12/22	CI
Qurient Co., Ltd. Enters into A Clinical Collaboration Agreement with Merck & Co., Inc. for Clinical Study of Q901	14/09/22	CI
Qurient Co. Ltd. U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy	08/02/22	CI
Qurient Co., Ltd. announced that it has received KRW 12.5 billion in funding from CureBio Co.,Ltd., and other investors	16/12/21	CI
Qurient Co., Ltd. announced that it expects to receive KRW 12.5 billion in funding from CureBio Co.,Ltd., and other investors	08/12/21	CI
Qurient Co. Ltd. Enters into A Clinical Collaboration Agreement with MSD	22/11/21	CI
Qurient Co., Ltd.(KOSDAQ:A115180) dropped from S&P Global BMI Index	07/07/21	CI
Qurient Co., Ltd. Enrolls First Patient in Q702 U.S. Phase 1 Study	26/01/21	CI
Qurient Co., Ltd. announced that it expects to receive KRW 59.99986805 billion in funding from a group of investors	21/09/20	CI
QLi5 Therapeutics GmbH announced that it expects to receive KRW 2.039115 billion in funding from Qurient Co., Ltd.	10/06/20	CI
Qurient Co., Ltd. Announces U.S. FDA Clearance of IND Application for Q702	26/05/20	CI
W Asset Management Co., Ltd. acquired 5.13% stake in Qurient Co., Ltd..	27/10/19	CI
Qurient Co., Ltd. Announces Positive Phase 2a Data of Novel Antibiotic for the Treatment of Tuberculosis	03/06/19	CI
Quad Investment Management Corporation acquired additional 9.1% stake in Qurient Co., Ltd..	22/10/18	CI
Qurient Co., Ltd. announced that it has received KRW 39.9999072 billion in funding	18/10/18	CI
Qurient Co., Ltd. announced that it expects to receive KRW 39.9999072 billion in funding	05/09/18	CI

Chart Qurient Co., Ltd.

Duration

Period

More charts

Company Profile

Qurient Co., Ltd. is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
QURIENT CO., LTD.	-20.99%	87.47M
MCKESSON CORPORATION	+29.50%	77.77B
CARDINAL HEALTH, INC.	+0.30%	24.62B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+14.70%	8.75B
SINOPHARM GROUP CO. LTD.	+0.73%	8.35B
HUADONG MEDICINE CO., LTD	-28.87%	7.1B
H. LUNDBECK A/S	+16.06%	5.25B
GALENICA AG	+1.58%	4.1B
EBOS GROUP LIMITED	-8.90%	3.8B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-7.62%	3.39B